<DOC>
	<DOCNO>NCT02486432</DOCNO>
	<brief_summary>A Single Period Investigation Assess Tolerability Healthy Subjects Oral Sinemet® ( Levodopa/Carbidopa ) Doses Administered Using Divided Dose Approach</brief_summary>
	<brief_title>A Single Period Investigation Assess Tolerability Healthy Subjects Oral Sinemet® ( Levodopa/Carbidopa )</brief_title>
	<detailed_description>This single centre , open-label , single period study healthy subject . Each subject receive follow regimen : On Day -2 , 10 mg domperidone administer every 8 hour 3 time day ( illustrative purpose , dose 07:30 , 15:30 23:30 ) On Day -1 , 3 dos 100 mg Sinemet® ( every 8 hour ) administer 2 × Sinemet® 12.5 mg/50 mg tablet contain 13.5 mg carbidopa ( equivalent 12.5 mg anhydrous carbidopa ) 50 mg levodopa . Subjects receive concomitant 10 mg domperidone 30 minute every Sinemet® dose . On Day 1 , Sinemet® 12.5 mg/50 mg contain 13.5 mg carbidopa ( equivalent 12.5 mg anhydrous carbidopa ) 50 mg levodopa administer every hour 16 consecutive dos ( total dose 800 mg ) . Subjects also receive concomitant domperidone 20 mg 30 minute first Sinemet® 50 mg dose every 8 hour ( total 3 dos ) treatment initiation . It plan enrol 6 subject ensure 6 evaluable subject . A subject consider evaluable receive 16 Sinemet® 50 mg dos .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>1 . Healthy male nonpregnant , nonlactating healthy female 2 . Age 40 65 year age 3 . Body mass index 18.0 35.0 kg/m2 , outside range , consider clinically significant investigator 4 . Must willing able communicate participate whole study 5 . Must provide write informed consent 6 . Must agree use adequate method contraception 1 . Participation clinical research study within previous 3 month 2 . Subjects study site employee , immediate family member study site sponsor employee 3 . Subjects previously enrol study 4 . History drug alcohol abuse past 2 year 5 . Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) 6 . Current smoker smoke within last 12 month . A breath carbon monoxide read great 10 ppm screen 7 . Females childbearing potential pregnant lactating ( female subject must negative urine pregnancy test admission ) 8 . Clinically significant abnormal biochemistry , haematology urinalysis judge investigator ( laboratory parameter list Appendix 1 ) 9 . Positive drug abuse test result ( drug abuse test list Appendix 1 ) 10 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result 11 . History cardiovascular , renal , hepatic , chronic respiratory GI disease judge investigator 12 . Serious adverse reaction serious hypersensitivity drug formulation excipients 13 . Presence history clinically significant allergy require treatment , judge investigator . Hayfever allow unless active 14 . Donation loss great 400 mL blood within previous 3 month 15 . Subjects take , take , prescribed overthecounter drug ( 4 g per day paracetamol , hormone replacement therapy hormonal contraception ) herbal remedy 14 day IMP administration ( See Section 11.4 ) 16 . Use nonselective monoamine oxidase ( MAO ) inhibitor within 2 week screen 17 . History presence glaucoma 18 . History presence suspicious undiagnosed skin lesion history melanoma 19 . Any history psychoses seizure 20 . Known hypersensitivity Sinemet® domperidone excipients 21 . Any history presence Prolactinreleasing pituitary tumour ( prolactinoma ) 22 . Any medical history GI haemorrhage , mechanical obstruction perforation 23 . Any history moderate severe hepatic impairment 24 . Subjects clinically significant liver function test 25 . Subjects QTc &gt; 450 m screen Sponsor/Quotient Clinical Confidential Protocol ND0612013 ( QCL117546 ) Version 1.0 02 FEB 2015 Page 23 42 26 . Subjects significant electrolyte disturbance 27 . Subjects underlie cardiac disease 28 . Subjects receive QTprolonging drug potent cytochrome P450 ( CYP ) 3A4 inhibitor within 4 week screen 29 . Failure satisfy investigator fitness participate reason</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>